Non-alcoholic fatty liver disease.

Area of Science:

• Hepatology
• Metabolic Syndrome
• Gastroenterology

Background:

• Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition characterized by hepatic steatosis unrelated to alcohol consumption.
• Its global prevalence is significant, reaching up to 30% in developed nations, making it the most common liver disorder worldwide.
• NAFLD pathogenesis is closely linked to insulin resistance, central obesity, and type 2 diabetes, involving complex lipid metabolism disruptions and cellular stress pathways.

Purpose of the Study:

• To provide a comprehensive overview of the current understanding of Non-alcoholic fatty liver disease (NAFLD).
• To discuss the pathogenesis, clinical presentation, diagnostic challenges, and treatment strategies for NAFLD and its progressive form, non-alcoholic steatohepatitis (NASH).
• To highlight the association of NAFLD with metabolic risk factors and its implications for cardiovascular health and diabetes development.

Main Methods:

• Review of existing literature on NAFLD epidemiology, pathophysiology, and clinical aspects.
• Analysis of histological spectrum from simple steatosis to NASH with fibrosis.
• Evaluation of current diagnostic methods, including liver biopsy and emerging non-invasive markers.
• Assessment of treatment approaches focusing on lifestyle modifications and pharmacological interventions.

Main Results:

• NAFLD affects a substantial portion of the global population and is strongly associated with metabolic dysfunction.
• The disease spectrum ranges from simple fatty liver to non-alcoholic steatohepatitis (NASH), which carries a risk of progression to cirrhosis and hepatocellular carcinoma.
• While liver biopsy remains the gold standard for NASH diagnosis, non-invasive markers like cytokeratin-18 show potential.
• Weight loss, exercise, and certain medications like pioglitazone and vitamin E may improve liver histology in NASH, but long-term efficacy requires further study.

Conclusions:

• NAFLD is a major global health concern driven by metabolic factors, with significant implications for liver-related and cardiovascular morbidity.
• Early detection and management of underlying metabolic derangements are crucial for preventing disease progression.
• Further research is needed to establish definitive long-term treatments and refine non-invasive diagnostic tools for NASH.